Regeneron Pharmaceuticals (REGN +0.9%) and collaboration partner Sanofi (SNY) announce new longer-term data from a Phase 2 clinical trial evaluating PD-1 inhibitor Libtayo (cemiplimab-rwlc) in patients with advanced cutaneous squamous cell carcinoma (CSCC).
Based on a follow-up period up to three years, the
objective response rate (ORR) was 46% (n=89/193) with a median time to
response of two months. The complete response rate was 16% (n=31/193).
Median duration of response and median overall survival (OS) have not
been reached.
Early this month, the companies announced positive data in patients with basal cell carcinoma, the most common type of skin cancer.
#ASCO20
https://seekingalpha.com/news/3578703-regeneron-and-sanofis-cemiplimab-shows-benefit-in-type-of-skin-cancer
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.